GSK Inks $3 Billion Shingles Vaccine Deal with China's Zhifei
China's largest vaccines company, Zhifei, has signed a deal with British drugmaker GSK worth $3.05 billion for the exclusive rights to distribute GSK's shingles vaccine, Shingrix, in China. The agreement aims to expand the availability of the vaccine from 9,500 to over 30,000 locations across China. GSK's Shingrix is its top-selling medicine and the deal with Zhifei is part of GSK's strategy to achieve over $4.88 billion in sales by 2026. The agreement also grants GSK the right of first refusal for any co-development of an RSV vaccine for older adults in China.